Connect vascular tone, ventricular loading and the body’s response. Use the same seven questions to explain the drugs, compare them and predict what changes in the patient.
Nicholas B. Norgard, PharmD · Companion to the vasodilator lecture
The same seven questions
Before the drug: identify the physiological problem. Is the ventricle struggling with filling pressure, ejection load, oxygen demand or pulmonary vascular resistance?
TargetWhere does it act?
ActionWhat does it do there?
Tissue effectWhat changes directly?
Body responseHow does the body respond?
Uses and outcomesWho benefits, and how?
SafetyWhat could go wrong?
PharmacokineticsHow does exposure change the response?
Distinguish direct effect from body response. Arteriolar relaxation is a tissue effect. The resulting reflex tachycardia and sodium-water retention are compensatory body responses. Pharmacokinetics changes exposure upstream; it is not simply the last event in the chain.
Veins → filling
Venous dilation increases reservoir capacity, reducing venous return and ventricular filling. Lower filling pressure can relieve congestion; excessive unloading can reduce output.
Arterioles → ejection
Arteriolar dilation reduces resistance opposing ejection. An afterload-sensitive ventricle may eject more blood without increased intrinsic contractility.
Evidence → benefit
A lower pressure or better flow is a physiological result. Survival and hospitalization claims require trials with a defined population and comparator.
Terms used throughout: preload = ventricular filling/stretch before contraction; afterload = the load opposing ejection; SVR = systemic vascular resistance; PVR = pulmonary vascular resistance; LV/RV = left/right ventricle; HFrEF = heart failure with reduced ejection fraction; GDMT = guideline-directed medical therapy; PK = pharmacokinetics (drug exposure over time); PD = pharmacodynamics (what the drug does); PAH = pulmonary arterial hypertension. NO = nitric oxide; sGC = soluble guanylyl cyclase; cGMP/cAMP = cyclic GMP/AMP, intracellular second messengers.
How to use this guide
Explain one prototype. Start with the physiology, then trace the seven steps in connected sentences.
Change one condition. Compare a nearby drug, a different route, renal function, ventricular loading or continuous versus interrupted exposure.
Predict before revealing. Attempt each practice task and self-check. Explain why the alternatives fail before opening the feedback.
Return to the figure. Each class links directly to the corresponding lecture views. Use the lecture’s Explanation for the short teaching account, prediction question and optional detailed context.
The lecture’s Reading view collects the figures and explanations in sequence. This Study guide reorganizes the material by class and comparison. Answers and sources are collapsed while studying and included when printing.
Independent study: answer, then explain
The companion question bank adds 24 framework questions and 16 Step 1–style clinical vignettes. Choose an answer before reading feedback, compare the explanation for every choice, and revisit the linked lecture view when needed.
Filter by topic, retry questions and track your answers in this browser. Print a question set with a separate answer key. The guide’s short self-checks reinforce each class; the bank provides additional practice across mechanisms, exposure, safety and clinical evidence.
Starting point: The myocardium needs oxygen to generate pressure and eject blood. A larger, more highly stressed ventricular wall needs more oxygen. Lowering filling can reduce that work even when a coronary stenosis remains.
Connect the steps Bioactivation supplies the signal; the vascular bed determines which load falls; repeated exposure changes responsiveness.
1 · TargetWhere does it act?
After bioactivation, an NO-related signal engages soluble guanylyl cyclase (sGC) in vascular smooth muscle. NTG has an important ALDH2-dependent pathway. ISDN and ISMN are less dependent on that pathway; a single dominant human activation route should not be assumed for them.
2 · ActionWhat does it do there?
sGC increases cGMP, activating protein kinase G (PKG). Changes in calcium signaling and myosin regulation reduce smooth-muscle contractile activation. Oral availability and bioactivation are separate concepts: well-absorbed ISMN still needs activation.
3 · Tissue effectWhat changes directly?
At usual antianginal exposure, venous dilation predominates. The venous reservoir holds more blood, reducing venous return, ventricular filling and wall stress. This mainly improves angina by lowering oxygen demand. Greater exposure adds arterial unloading; relief of coronary spasm can also improve supply.
4 · Body responseHow does the body respond?
A pressure fall can trigger reflex tachycardia and volume-retaining responses. Continuous exposure can produce tolerance: the same exposure gives less effect. Oxidative changes and altered bioactivation/signaling contribute; compensation also matters. Different isosorbide bioactivation does not eliminate tolerance.
5 · Uses and outcomesWho benefits, and how?
Sublingual NTG provides rapid angina relief. Oral isosorbides and transdermal NTG provide prevention. IV NTG permits monitored unloading in selected acute settings, including congestion when pressure permits. Chronic HFrEF outcome evidence belongs to hydralazine plus ISDN, not to all nitrate regimens.
6 · SafetyWhat could go wrong?
Headache, dizziness and hypotension follow vasodilation. Preload-dependent patients, including those with RV infarction, can lose cardiac output with venous unloading. Nitrates must not be combined with PDE-5 inhibitors or riociguat because excessive cGMP signaling can cause profound hypotension.
7 · PharmacokineticsHow does exposure change the response?
Route shapes onset and duration. Sublingual NTG avoids initial hepatic first pass; ISDN undergoes substantial first-pass metabolism and forms active mononitrates; ISMN has more predictable oral availability. NTG patches commonly use 12–14 hours on and 10–12 hours off. Oral schedules are formulation specific. The low-exposure interval limits tolerance but leaves a gap in nitrate coverage.
Apply the pathway
Practice task: Explain why a patient can have improved angina with lower ventricular filling and no increase in absolute coronary flow.
Learning goal: Connect venous pooling to wall stress and oxygen demand, then add the consequences of pressure reduction and repeated exposure.
Self-check
A maintenance NTG patch initially works well, but its effect fades during uninterrupted exposure. Which explanation best fits tolerance?
The patch must have stopped delivering drug.
The same exposure can produce less effect because of vascular adaptation and compensation.
Isosorbide preparations cannot show this problem because they activate differently.
Show explanation
A. A delivery failure is possible in practice, but it is not required to explain tolerance.
B. Correct. Tolerance concerns the exposure–response relationship; persistent drug does not guarantee persistent effect.
C. Isosorbide nitrates can also develop tolerance. Shared downstream adaptation and compensation extend beyond the NTG–ALDH2 pathway.
Starting point: A second messenger has both a source and a removal pathway. NO–sGC signaling produces cGMP; phosphodiesterase type 5 (PDE-5) breaks it down.
Connect the steps Preserving a messenger differs from generating it. Combining those two interventions can amplify both benefit and harm.
1 · TargetWhere does it act?
PDE-5, an enzyme responsible for cGMP degradation in relevant smooth-muscle tissues.
2 · ActionWhat does it do there?
Inhibit cGMP breakdown, prolonging and amplifying an existing NO–cGMP signal. These drugs do not directly synthesize NO.
3 · Tissue effectWhat changes directly?
More sustained cGMP signaling favors smooth-muscle relaxation. The intended tissue and product determine whether the application is erectile function, pulmonary vascular resistance or another approved use.
4 · Body responseHow does the body respond?
Systemic pressure can fall even when the intended effect is local or pulmonary. Do not assume that a tissue-focused indication guarantees tissue-exclusive action.
5 · Uses and outcomesWho benefits, and how?
All four agents have erectile-dysfunction uses. Sildenafil and tadalafil also have products indicated for pulmonary arterial hypertension. Tadalafil has a benign prostatic hyperplasia indication. Specify the agent, product and regimen rather than assigning every use to the entire class.
6 · SafetyWhat could go wrong?
Headache, flushing and hypotension reflect vasodilation. Nitrates and riociguat are contraindicated combinations. Priapism and sudden vision or hearing changes are important serious warnings. Individual products have additional precautions, such as QT concerns with vardenafil.
7 · PharmacokineticsHow does exposure change the response?
The interaction lasts as long as clinically relevant inhibition persists. Tadalafil has a longer persistence than the shorter-acting agents. The nitrate restriction is agent and exposure dependent; do not apply one universal washout interval to the class.
Apply the pathway
Practice task: Compare adding a nitrate with adding an sGC stimulator to PDE-5 inhibition. Identify the shared reason for excessive vasodilation.
Learning goal: Trace increased cGMP production plus reduced cGMP removal without confusing the three molecular targets.
Self-check
Why can NTG cause a much larger BP fall in a person with clinically relevant PDE-5 inhibition?
cGMP production increases while its breakdown is inhibited.
PDE-5 inhibition prevents NTG from reaching the circulation.
The combination blocks cardiac β₁ receptors.
Show explanation
A. Correct. The two drugs amplify the same messenger from opposite sides of its turnover.
B. The principal interaction is pharmacodynamic amplification, not prevention of nitrate absorption.
C. Neither mechanism is β₁ blockade. The dangerous fall in pressure follows excessive vasodilation.
Starting point: A congested, afterload-sensitive ventricle can have too much backward filling pressure and too little forward output. Venous and arterial dilation address different parts of that problem.
Connect the steps Follow two time courses: the rapidly adjustable vascular effect and the formation and clearance of toxic metabolites.
1 · TargetWhere does it act?
An NO-related signal from the iron–nitrosyl complex engages smooth-muscle sGC. Nitroprusside activation is distinct from the organic-nitrate ALDH2 pathway.
2 · ActionWhat does it do there?
Reductive and thiol-dependent processes support NO-related activity. sGC increases cGMP, promoting PKG-dependent relaxation.
3 · Tissue effectWhat changes directly?
Balanced venous and arterial dilation lowers both filling pressure and ejection resistance. In an afterload-sensitive failing ventricle, stroke volume can rise while LV and pulmonary venous pressures fall: less congestion and more forward flow.
4 · Body responseHow does the body respond?
The response depends on baseline ventricular function and filling. Reflex responses can occur, and excessive unloading can reduce output in a patient who needs preload. MAP can fall despite improved CO because SVR also falls.
5 · Uses and outcomesWho benefits, and how?
A titrated infusion supports rapid, monitored BP reduction and selected acute-HF unloading. Choose it for a defined hemodynamic problem, with sufficient pressure and continuous monitoring.
6 · SafetyWhat could go wrong?
Excessive hypotension is immediate. Cerebral vasodilation can increase intracranial pressure. Cyanide inhibits cellular oxygen utilization; methemoglobin impairs oxygen carriage; thiocyanate accumulation produces neurologic toxicity. These are different mechanisms and should not be collapsed into one oxygen problem.
7 · PharmacokineticsHow does exposure change the response?
The vascular effect rapidly follows infusion-rate changes and fades after stopping. Cyanide must first be detoxified to thiocyanate, which is cleared by the kidneys. High generation rates threaten cyanide handling; prolonged exposure and reduced renal clearance favor thiocyanate accumulation. Short vascular action does not imply short metabolite persistence.
Apply the pathway
Practice task: Describe how nitroprusside can move a patient toward higher cardiac output at a lower filling pressure, then explain why renal impairment still matters after good BP control is achieved.
Learning goal: Separate load-dependent benefit from exposure-dependent toxicity.
Self-check
A patient with reduced renal clearance receives a prolonged nitroprusside infusion. Which substance is especially prone to accumulation from impaired renal elimination?
cGMP as the principal renally retained toxin
Thiocyanate
ALDH2
Show explanation
A. cGMP mediates relaxation but is not the retained metabolite at issue here.
B. Correct. Renal elimination of thiocyanate is distinct from the preceding detoxification of cyanide.
C. ALDH2 is an enzyme discussed in NTG bioactivation, not the renally cleared nitroprusside metabolite.
Starting point: Low available NO can limit endogenous cGMP production. Increasing the responsiveness and activity of sGC provides another entry point into the same messenger pathway.
Connect the steps Keep the shared molecular action together, but attach the indication and outcome evidence to the individual drug.
1 · TargetWhere does it act?
The reduced, heme-containing form of sGC. These drugs are stimulators, distinct from heme-independent sGC activators.
2 · ActionWhat does it do there?
Enhance sensitivity to endogenous NO and directly stimulate sGC independently of NO. Both actions increase cGMP production; neither is PDE-5 inhibition.
3 · Tissue effectWhat changes directly?
Increased cGMP/PKG signaling favors smooth-muscle relaxation. Direct stimulation can support cGMP generation when available NO is low, provided responsive enzyme remains.
4 · Body responseHow does the body respond?
Vascular resistance and pressure can fall. The starting circulation and responsive sGC pool influence the result; a common signaling effect does not predict identical clinical benefit in pulmonary hypertension and HFrEF.
5 · Uses and outcomesWho benefits, and how?
Riociguat: pulmonary arterial hypertension (WHO Group 1) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgery (CTEPH; WHO Group 4). It is the only FDA-approved pulmonary vasodilator for CTEPH. Vericiguat: selected symptomatic chronic HF with EF below 45% after recent HF hospitalization or outpatient IV diuretics. In VICTORIA, adding it to background GDMT reduced the CV-death/HF-hospitalization composite; separate mortality benefit was not established.
6 · SafetyWhat could go wrong?
Hypotension and embryo-fetal toxicity are important. Riociguat must not be combined with nitrates or PDE-5 inhibitors. PDE-5 inhibitor combination with vericiguat is not recommended; vericiguat can also cause anemia. Use each agent’s specific restrictions.
7 · PharmacokineticsHow does exposure change the response?
Both are oral agents with titration and exposure considerations distinct from an immediately adjustable IV infusion. A shared target does not make dose schedules, interactions or persistence interchangeable.
Apply the pathway
Practice task: Assign PAH, CTEPH and recently worsening HFrEF to the appropriate agent. Explain why HFrEF GDMT language should not be placed in a shared class row.
Learning goal: Keep mechanism, population and trial endpoint linked without making a class-wide outcome claim.
Self-check
Which statement accurately describes vericiguat’s evidence in this lecture?
It replaces foundational HFrEF treatment.
It proved an independent mortality benefit for all drugs acting on sGC.
It reduced a composite of CV death or HF hospitalization when added to background therapy in recently worsening symptomatic HFrEF.
Show explanation
A. VICTORIA tested add-on treatment, not replacement of foundational therapy.
B. A composite benefit is not a separately proven mortality effect and cannot be transferred to another agent.
C. Correct. The drug, background therapy, population and composite endpoint all belong in the claim.
Starting point: Ventricular stress stimulates natriuretic peptide signaling. Lower filling pressure is useful physiology, but does not by itself establish that a therapy reduces death or hospitalization.
Connect the steps Use this history to distinguish receptor action, an improved measurement, and a demonstrated patient outcome.
1 · TargetWhere does it act?
Natriuretic peptide receptor A (NPR-A), which has membrane guanylyl cyclase activity. This is different from the soluble enzyme activated by NO.
2 · ActionWhat does it do there?
Recombinant BNP activates receptor-linked cGMP production. The messenger is shared with NO-related drugs, but the upstream receptor is different.
3 · Tissue effectWhat changes directly?
Vasodilation and natriuretic signaling can lower filling pressure. Early studies showed favorable hemodynamics and some symptom relief in acute decompensated HF.
4 · Body responseHow does the body respond?
Blood pressure may fall enough to limit benefit. Whole-patient responses must be measured; lower pulmonary capillary wedge pressure (PCWP) does not guarantee improved survival.
5 · Uses and outcomesWho benefits, and how?
The 2000 trial supported physiological promise, followed by FDA approval in 2001. VMAC (published 2002) found a modest PCWP advantage over NTG without better dyspnea than NTG. Outpatient use expanded before long-term benefit was established. In 2011, ASCEND-HF found no reduction in 30-day death/HF readmission. U.S. Natrecor is discontinued; FDA did not attribute discontinuation to safety or effectiveness.
6 · SafetyWhat could go wrong?
Hypotension remained an important adverse effect. The 2005 analyses raised renal and mortality concerns; the mortality signal was statistically uncertain. ASCEND-HF did not establish significant renal or mortality harm, but also did not establish the hoped-for clinical outcome benefit.
7 · PharmacokineticsHow does exposure change the response?
Nesiritide was administered intravenously. Its receptor-linked mechanism and treatment setting differ from oral sGC stimulation. Repeat outpatient infusions represented a separate use requiring its own evidence, not an automatic extension of short-term acute-HF hemodynamics.
Apply the pathway
Practice task: Tell the timeline in three sentences: early physiological promise, expansion and concern, then randomized outcome reassessment.
Learning goal: Distinguish lack of demonstrated benefit from proof of harm, while explaining why surrogate enthusiasm can outrun evidence.
Self-check
Which conclusion best follows from an intervention that lowers PCWP but fails to reduce death or HF readmission?
The hemodynamic effect must have been imaginary.
The surrogate change did not establish that clinical outcome benefit.
Every drug that lowers PCWP must be ineffective.
Show explanation
A. A real physiological effect can coexist with an absent or insufficient clinical benefit.
B. Correct. The endpoint and population tested determine the conclusion.
C. The result belongs to the studied intervention and comparison, not every treatment sharing one physiological effect.
Starting point: High pulmonary vascular resistance burdens the right ventricle. Blood flowing past poorly ventilated lung regions contributes little to oxygenation. Local delivery can change where vasodilation occurs.
Connect the steps Delivery determines which vessels receive NO; hemoglobin limits active NO beyond the lungs; interruption removes the effect quickly.
1 · TargetWhere does it act?
sGC in pulmonary vascular smooth muscle adjacent to ventilated alveoli.
2 · ActionWhat does it do there?
Inhaled NO diffuses locally, activates sGC and increases cGMP. PKG-mediated signaling reduces smooth-muscle contraction.
3 · Tissue effectWhat changes directly?
Pulmonary resistance and RV afterload fall. Preferential delivery to ventilated regions can redirect perfusion toward sites capable of gas exchange, improving ventilation–perfusion matching. NO does not open a collapsed alveolus.
4 · Body responseHow does the body respond?
Oxygenation can improve. More blood returning to a poorly accommodating LV can increase filling pressure and worsen pulmonary edema. Abrupt withdrawal can cause rebound pulmonary hypertension and worsening oxygenation.
5 · Uses and outcomesWho benefits, and how?
The U.S. indication is hypoxic respiratory failure with pulmonary hypertension in term and near-term neonates over 34 weeks’ gestation, with ventilatory support. Trials showed improved oxygenation and reduced ECMO need, not a separately established survival benefit. Selected adult RV support and hypoxemia rescue are off-label; better oxygenation has not established routine ARDS survival benefit.
6 · SafetyWhat could go wrong?
Monitor methemoglobin in blood and nitrogen dioxide in delivered gas: the former impairs oxygen carriage, the latter injures lungs. Reliable delivery and monitored weaning address rebound. Avoid in neonates whose systemic circulation depends on right-to-left shunting.
7 · PharmacokineticsHow does exposure change the response?
Continuous inhalation supplies a short-lived signal. Hemoglobin rapidly inactivates NO, limiting systemic delivery. Methemoglobin and nitrate form; nitrate is eliminated in urine. Metabolite elimination is distinct from the much faster disappearance of active NO.
Apply the pathway
Practice task: Explain pulmonary selectivity using both delivery and inactivation, then predict what a sudden delivery interruption can do.
Learning goal: Connect PK to location, duration and withdrawal risk rather than treating selectivity as an absolute property of the molecule.
Self-check
What best explains why inhaled NO can dilate pulmonary vessels with relatively little systemic vasodilation?
Only pulmonary vessels contain sGC.
NO remains active for days after absorption.
Local alveolar delivery is followed by rapid scavenging in blood.
Show explanation
A. sGC is not confined to the pulmonary circulation.
B. The active NO signal is short-lived; prolonged persistence would undermine this explanation of selectivity.
C. Correct. The route and rapid inactivation work together.
Starting point: Endothelial cells release endothelin-1, a potent local vasoconstrictor. Blocking its receptors reduces a constrictor signal rather than supplying NO.
Connect the steps A shared receptor family does not make indications, hepatic precautions or monitoring identical.
1 · TargetWhere does it act?
ETA receptors, or both ETA and ETB, depending on the drug. Ambrisentan preferentially blocks ETA; bosentan, macitentan and aprocitentan block both.
2 · ActionWhat does it do there?
Prevent endothelin-mediated receptor activation. ETA blockade reduces calcium-dependent contraction in vascular smooth muscle. Endothelial ETB also participates in vasodilator release and endothelin clearance, so it is not simply another copy of ETA.
3 · Tissue effectWhat changes directly?
Vascular resistance falls in the treated circulation. In PAH, this reduces the resistance against which the right ventricle ejects.
4 · Body responseHow does the body respond?
Systemic BP can fall and fluid retention can still develop. Lower resistance is not equivalent to lower total body sodium or freedom from edema.
5 · Uses and outcomesWho benefits, and how?
Bosentan, ambrisentan and macitentan treat pulmonary arterial hypertension, WHO Group 1. Aprocitentan is an add-on treatment for systemic hypertension inadequately controlled with other drugs. Do not transfer the PAH indication to every endothelin antagonist.
6 · SafetyWhat could go wrong?
Embryo-fetal toxicity, anemia and fluid retention are important. Hepatic risks and monitoring are agent specific. Bosentan has a particularly important hepatotoxicity warning and requires baseline and monthly aminotransferase assessment.
7 · PharmacokineticsHow does exposure change the response?
These are oral agents. Hepatic handling and interacting drugs can alter exposure; use the particular product’s interaction and monitoring requirements rather than assuming a class-wide regimen.
Apply the pathway
Practice task: Compare ambrisentan with aprocitentan: identify the receptor selectivity and clinical use of each without assuming that one difference explains every outcome.
Learning goal: Distinguish receptor action from indication and from whole-body fluid responses.
Self-check
A patient develops edema while taking an endothelin antagonist. Which interpretation is most appropriate?
Edema proves that vascular resistance increased.
Fluid retention can coexist with the intended reduction in vascular resistance.
All agents in the class have identical hepatic safety.
Show explanation
A. Edema does not determine the direction of the drug’s direct vascular effect.
B. Correct. Tissue relaxation and whole-body sodium-water balance are distinct outcomes.
C. Hepatic warnings and monitoring differ by agent and do not explain away the edema.
Direct arteriolar vasodilation · inherited NAT2 variation
Starting point: Resistance arterioles control much of the load opposing LV ejection. Relaxing them lowers afterload, but the pressure-sensing and renal systems respond to the fall in pressure.
Connect the steps The tissue effect predicts unloading; compensation predicts companion therapy; inherited metabolism predicts variable exposure and dose needs.
1 · TargetWhere does it act?
Arteriolar smooth muscle is the major functional site. A single precise molecular target is not established.
2 · ActionWhat does it do there?
Directly relax arteriolar smooth muscle through incompletely defined molecular mechanisms. Do not invent a named receptor to fill the target row.
3 · Tissue effectWhat changes directly?
Systemic resistance and LV afterload fall; veins are relatively spared. An afterload-sensitive ventricle may eject more effectively without a direct increase in intrinsic contractility.
4 · Body responseHow does the body respond?
Reduced arterial stretch triggers sympathetic activation, increasing heart rate, cardiac work and renin release. Hormonal sodium-water retention can produce edema. A beta blocker and diuretic can address different components of this compensation in an appropriate regimen.
5 · Uses and outcomesWho benefits, and how?
Selected hypertension treatment; IV use in hypertensive emergencies, especially acute severe hypertension in preeclampsia. Outside pregnancy, bolus dosing, unpredictable response and prolonged action limit precise acute control. In HFrEF, outcome evidence applies to combination with ISDN.
6 · SafetyWhat could go wrong?
Tachycardia/angina and retention follow compensation. Drug-induced lupus is a separate immune-mediated toxicity: a classic cohort estimated 6.7% over three years, influenced by dose and susceptibility. Peripheral neuropathy may involve functional vitamin B₆ availability; U.S. labeling recommends pyridoxine if symptoms develop but provides no reliable numerical incidence.
7 · PharmacokineticsHow does exposure change the response?
The NAT2 gene influences acetylation and first-pass inactivation. Slow acetylators generally have higher active-drug exposure and may need lower oral doses; rapid acetylators may need higher doses. NAT2 is one reason the same dose gives variable BP responses. Individualize to response and tolerability; slower acetylation also contributes to lupus susceptibility.
Apply the pathway
Practice task: Explain different BP responses to the same oral dose in two patients, then link the exposure difference to lupus risk without treating genotype as destiny.
Learning goal: Connect inherited PK to variable response and dosing, while separating reflex adverse effects from immune toxicity.
Self-check
Compared with a rapid acetylator, a slow NAT2 acetylator receives the same oral hydralazine dose. What is generally expected?
Greater parent-drug exposure and potentially a greater BP response
A new vascular molecular target
Guaranteed development of lupus
Show explanation
A. Correct. Reduced inactivation changes exposure and can change dose requirements.
B. The PK difference changes how much drug reaches its sites of action, not what vascular target it has.
C. Higher exposure and acetylator status contribute to risk; neither guarantees an immune adverse effect.
Complementary unloading · trial-defined HFrEF role
Starting point: A failing LV may face both high filling pressure and excessive ejection load. Combining two vascular patterns is physiologically reasonable, but the population and comparison in outcome trials still determine clinical use.
Connect the steps Follow the evidence sequence: V-HeFT I overall → V-HeFT II overall → retrospective subgroups → prospective A-HeFT add-on trial.
1 · TargetWhere does it act?
Hydralazine acts predominantly in arteriolar smooth muscle. Bioactivated ISDN engages the NO–sGC pathway in vascular smooth muscle.
2 · ActionWhat does it do there?
Combine direct arterial relaxation with nitrate-mediated cGMP signaling. Experimental nitroso–redox effects provide a possible additional mechanism; they do not by themselves explain the survival benefit.
3 · Tissue effectWhat changes directly?
Hydralazine lowers the resistance opposing ejection; ISDN adds predominant venous pooling to lower filling pressure and wall stress. Forward output and pulmonary congestion can improve through complementary changes in loading.
4 · Body responseHow does the body respond?
Reflex activation and retention still matter. Low BP, headache and the demands of a multidose regimen can limit the achieved treatment exposure.
5 · Uses and outcomesWho benefits, and how?
V-HeFT I: the prespecified two-year mortality comparison favored H–ISDN over placebo (25.6% vs 34.3%). V-HeFT II: enalapril had lower two-year mortality than H–ISDN (18% vs 25%). Retrospective racial subgroup observations helped motivate A-HeFT, which prospectively tested add-on therapy in 1,050 self-identified Black patients and found mortality of 6.2% vs 10.2%, with fewer first HF hospitalizations. Current use includes selected Black patients with persistent NYHA III–IV HFrEF symptoms despite optimal therapy; an alternative role when ARNI/ACE inhibitor/ARB therapy cannot be used has less direct evidence.
6 · SafetyWhat could go wrong?
Combine the safety concerns of both drugs: headache, hypotension, dangerous nitrate interactions and hydralazine-specific lupus or neuropathy. A favorable mechanistic rationale does not eliminate adverse effects.
7 · PharmacokineticsHow does exposure change the response?
Hydralazine exposure varies with NAT2 metabolism; ISDN has first-pass handling and active metabolites. The actual schedule, adherence and tolerability affect exposure to both drugs. Evidence for an ISDN regimen must not automatically be transferred to ISMN.
Apply the pathway
Practice task: For each trial, state the population, comparator, background treatment and outcome. Explain why a retrospective subgroup result is not equivalent to prospective randomized confirmation.
Learning goal: Use the curves with the correct endpoint and time horizon, and distinguish self-identified race from a measured biological mechanism.
Self-check
Why is A-HeFT a different clinical question from V-HeFT II?
A-HeFT tested whether ISMN was equivalent to ISDN.
A-HeFT replaced all background therapy with a nitrate.
A-HeFT tested adding H–ISDN versus placebo to background therapy in a prospectively defined population.
Show explanation
A. That was not the randomized comparison; the outcome evidence belongs to the ISDN combination.
B. It was an add-on study, not withdrawal of foundational treatment.
C. Correct. V-HeFT II instead compared enalapril with the combination on the background therapy of its era.
Starting point: Voltage-dependent calcium entry supports arteriolar contraction. Altering potassium conductance changes membrane voltage and can reduce calcium entry indirectly.
Connect the steps Name the potassium-channel action first, then follow the voltage and calcium changes before adding the baroreflex and renal responses.
1 · TargetWhere does it act?
ATP-sensitive potassium channels (KATP) in arteriolar smooth muscle, acted on by the active sulfate metabolite.
2 · ActionWhat does it do there?
Minoxidil sulfate increases potassium conductance. Potassium efflux hyperpolarizes the membrane, reducing voltage-dependent calcium-channel opening. It is not a direct calcium-channel blocker.
3 · Tissue effectWhat changes directly?
Less calcium entry reduces calcium-dependent contractile activation. Arterioles relax strongly, lowering SVR and afterload while relatively sparing veins. Renal resistance vessels also dilate.
4 · Body responseHow does the body respond?
A strong pressure fall triggers sympathetic activation and renin release. Tachycardia, increased cardiac work and substantial sodium-water retention can undermine the direct benefit. Preserved renal flow does not guarantee net sodium loss.
5 · Uses and outcomesWho benefits, and how?
U.S. labeling reserves oral antihypertensive treatment for inadequate control despite maximum therapeutic doses of a diuretic and two other antihypertensives. Topical scalp treatment has a different purpose and exposure pattern: local hair growth.
6 · SafetyWhat could go wrong?
Systemic treatment generally requires a sympathetic suppressant, usually a beta blocker, and an effective diuretic. Serious risks include angina exacerbation and pericardial effusion, potentially progressing to tamponade. Hypertrichosis is characteristic but distinct from these cardiovascular harms.
7 · PharmacokineticsHow does exposure change the response?
Bioactivation generates minoxidil sulfate. Oral antihypertensive exposure is systemic; topical scalp exposure is much lower and depends on formulation, application and skin condition. Do not teach the two routes as equivalent regimens.
Apply the pathway
Practice task: Explain why a beta blocker plus a diuretic may be needed, and why that pairing does not eliminate pericardial toxicity.
Learning goal: Distinguish target action, predictable compensation and a separate serious adverse effect.
Self-check
Which causal sequence correctly explains minoxidil’s arteriolar relaxation?
Starting point: Dopamine-receptor signaling can relax systemic and renal resistance vessels. Receptor selectivity determines whether a drug predominantly dilates vessels or adds cardiac and vasoconstrictor actions.
Connect the steps Separate renal blood flow and sodium excretion from proof of renal outcome benefit; separate fenoldopam from dopamine’s broader receptor actions.
1 · TargetWhere does it act?
Peripheral D₁-like dopamine receptors, including vascular and renal sites.
2 · ActionWhat does it do there?
Activate Gs and adenylyl cyclase to increase cAMP. This differs from the cGMP pathway used by NO-related vasodilators.
3 · Tissue effectWhat changes directly?
Systemic and renal vascular resistance fall. Renal blood flow and sodium excretion can increase. These are physiological effects rather than proof that kidney injury is prevented.
4 · Body responseHow does the body respond?
Reflex tachycardia can follow the pressure fall even without direct β₁ stimulation. Increased urinary electrolyte loss can contribute to hypokalemia.
5 · Uses and outcomesWho benefits, and how?
Short-term IV treatment of severe hypertension. Fenoldopam is a BP-lowering vasodilator, not a dopamine-like pressor; it lacks dopamine’s clinically meaningful β₁ and α₁ agonist effects.
6 · SafetyWhat could go wrong?
Hypotension, reflex tachycardia, hypokalemia and increased intraocular pressure (pressure inside the eye). Glaucoma is a particular concern. Beta-blocker coadministration may exaggerate hypotension, so minoxidil’s usual pairing rule should not be transferred automatically.
7 · PharmacokineticsHow does exposure change the response?
A short duration of action permits infusion titration and prompt adjustment of the vascular effect. Exposure control supports monitored acute use; it does not establish a chronic renal-protective outcome.
Apply the pathway
Practice task: Compare fenoldopam, minoxidil and hydralazine. Start with their different entry points, then identify one safety or exposure distinction for each.
Learning goal: Recognize convergence at arteriolar relaxation without assuming interchangeable regimens or outcomes.
Self-check
A drug increases renal blood flow during BP reduction. What additional evidence is needed before claiming it prevents clinically important kidney injury?
No further evidence; the flow change proves it.
A study measuring the relevant renal clinical outcomes
Evidence that every patient develops reflex tachycardia
Show explanation
A. A physiological measurement is not a validated substitute for every clinical outcome.
B. Correct. The renal-outcome claim must be tested rather than inferred solely from perfusion.
C. Tachycardia is a compensatory response and cannot establish kidney protection.
Name the drug, then explain which clue separates it from its nearest alternative.
Clue 1
I relieve an acute angina episode by rapidly reducing ventricular filling and wall stress. My sublingual route avoids initial hepatic first-pass metabolism.
Reveal answer and reasoning
Sublingual nitroglycerin
Rapid exposure supports rescue. Predominant venous dilation lowers preload and oxygen demand; a maintenance patch has a different time course.
I lower both filling pressure and ejection resistance during an adjustable IV infusion. My vascular effect disappears much faster than all of my metabolites do.
Reveal answer and reasoning
Sodium nitroprusside
Balanced dilation can relieve congestion and improve forward flow. Cyanide handling and renal thiocyanate clearance remain separate safety concerns.
My pulmonary selectivity depends on inhalation beside ventilated alveoli and rapid hemoglobin scavenging. Abrupt interruption can cause rebound pulmonary hypertension.
Reveal answer and reasoning
Inhaled nitric oxide
Both delivery and inactivation matter. The same short-lived signal that limits systemic exposure makes continuous delivery and monitored weaning important.
Inherited NAT2 activity helps explain why equal oral doses produce different exposure, BP responses and dose requirements. My direct vascular effect mainly involves arterioles.
Reveal answer and reasoning
Hydralazine
Acetylation changes parent-drug exposure. Slow acetylation also contributes to lupus susceptibility, which is separate from reflex tachycardia.
My active sulfate metabolite opens KATP channels. Oral antihypertensive use usually requires treatment of marked tachycardia and retention, and carries a pericardial-effusion warning.
Reveal answer and reasoning
Minoxidil
KATP opening hyperpolarizes smooth muscle and reduces calcium entry. Companion drugs address compensation but do not eliminate every toxicity.
I increase cAMP through D₁-like receptors and can increase renal blood flow while lowering severe BP. Increased intraocular pressure is one of my safety concerns.
Reveal answer and reasoning
Fenoldopam
D₁–Gs–adenylyl cyclase signaling distinguishes it from NO–cGMP drugs. Renal hemodynamic effects do not prove renal protection.
I am recombinant BNP and activate a membrane guanylyl cyclase. Early reductions in filling pressure encouraged adoption before later trials tested the hoped-for outcome benefit.
Reveal answer and reasoning
Nesiritide
NPR-A is distinct from soluble GC. ASCEND-HF illustrates why improved hemodynamics do not automatically establish fewer deaths or HF readmissions.
Change one part of the causal chain and explain why the prediction changes. Attempt each comparison before opening the reasoning.
Change the vascular bed
Compare a predominantly venous nitrate effect, hydralazine’s arterial effect and nitroprusside’s balanced effect in a congested, afterload-sensitive ventricle. Which load changes first in each case?
Reveal reasoning
Predominant venous dilation redistributes blood away from the heart and lowers filling pressure. Arteriolar dilation reduces the load opposing ejection. Balanced dilation changes both, so output can improve at a lower filling pressure. Starting BP, preload dependence and ventricular function determine whether unloading is tolerated.
Compare an NO-related drug, an sGC stimulator, a PDE-5 inhibitor and nesiritide. How can all affect cGMP while acting at different points?
Reveal reasoning
An NO-related signal activates sGC. A stimulator increases reduced, heme-containing sGC activity and sensitivity to NO. A PDE-5 inhibitor slows cGMP removal. Nesiritide activates NPR-A, a membrane guanylyl cyclase. Shared cGMP signaling does not make the targets, interactions or indications identical.
Compare a fading nitrate response during continuous exposure, an exaggerated hydralazine response in a slow acetylator, and thiocyanate accumulation in renal impairment. Are these the same PK problem?
Reveal reasoning
No. Nitrate tolerance changes the response to a continuing exposure through adaptation and compensation. Slow acetylation can increase hydralazine parent-drug exposure by reducing inactivation. Impaired renal clearance can increase thiocyanate metabolite exposure. Distinguish altered responsiveness, parent-drug handling and metabolite handling.
Explain why a favorable physiological mechanism, a retrospective subgroup signal and a prospective add-on trial support different kinds of conclusions.
Reveal reasoning
A mechanism supports a prediction but does not establish clinical benefit. A retrospective subgroup can suggest a question, but separate significant/nonsignificant P values do not establish a treatment interaction. A prospective randomized trial tests a defined comparison in a specified population. Keep the endpoint, time horizon and background treatment attached to the claim, as in V-HeFT, A-HeFT and ASCEND-HF.
Can you identify the target or established functional site, connect it to the vascular effect, add relevant compensation, name a supported benefit, predict a major harm and identify an exposure change that matters? The seven answers need not be equally long; the causal links should be clear.